AI-Powered Precision Cell Therapy
Driving a transformation in solid tumor cancer treatment by targeting clonal neoantigens present on all cancer cells to develop precision T cell therapies
More Info +
Driving a transformation in solid tumor cancer treatment by targeting clonal neoantigens present on all cancer cells to develop precision T cell therapies
More Info +Achilles Therapeutics is a biopharmaceutical company developing precision T cell therapies that target clonal neoantigens. Neoantigens are protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumor evolution which allows us to leverage our bioinformatics platform - powered by artificial intelligence (AI) - to identify ‘clonal’ neoantigens that arise early in cancer development and are retained as each tumor continues to grow and mutate. By directing T cell therapies against clonal neoantigens, which are present on all cancer cells and are completely absent from normal cells, we can for the first time target every cancer cell without attacking healthy tissue.
About Us +
Eric Tran, Simon Turcotte, Alena Gros, Paul F. Robbins, Yong-Chen Lu, Mark E. Dudley... plus more
View Publication +Nikolaos Zacharakis, Harshini Chinnasamy, Mary Black, Hui Xu, Yong-Chen Lu, Zhili Zheng... plus more
View Publication +Eric Tran, Ph.D., Paul F. Robbins, Ph.D., Yong-Chen Lu, Ph.D., Todd D. Prickett, Ph.D... plus more
View Publication +Achilles Therapeutics was founded by world-leading experts in cancer evolution, bioinformatics, and the development of cell-based immunotherapies. The company brings together genomics, AI, and cell therapy to develop next-generation, patient-specific cell therapies that harness and focus the immune system to destroy cancer cells without attacking healthy tissue.
More Info +Co-founder Charlie Swanton speaks about his career, the advent of immunotherapy and what the Achilles team are looking to achieve
Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells. This marks a significant milestone for Achilles, delivering the first precision TIL therapy.